Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data

Cephalalgia 2022 Sep 8;3331024221123058. doi: 10.1177/03331024221123058. Online ahead of print. Michel Lanteri-Minet, Anne Ducros , Clement Francois, Elzbieta Olewinska, Mateusz Nikodem, Laure Dupont-Benjamin Abstract Background: This meta-analysis evaluated the real-world effectiveness of onabotulinumtoxinA (BOTOX®), the first preventive treatment FDA-approved specifically for chronic migraine in 2010.

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny